FDA grants orphan drug designation for asedebart in Cushing’s syndrome
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
08:23:02 AM UTC
SquawkNews
VALBY, Denmark, Sept. 11, 2026 // -- Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syn…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.